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The COVID epidemic is affecting individuals worldwide, and Alzheimer’s disease (AD) and 
amnesic mild cognitive impairment (MCI) patients are at risk due to their characteristics and age. 
We analysed the impact of the pandemic on these patients’ neuropsychiatric symptoms and their 
quality of life after five weeks of lockdown in Spain.
Methods
We tested 40 subjects with a diagnosis of MCI (20) or mild AD (20) from the Cognitive 
Stimulation Program of Cognitive Disorders Unit. All patients had undergone a previous 
evaluation during the month before the lockdown, and they were re-evaluated after 5 weeks of 
lockdown. The Neuropsychiatric Inventory (NPI) and EuroQol-5D were used to evaluate the 
neuropsychiatric symptoms and quality of life of patients and caregivers.
Results
The total baseline NPI score was 33.75 (22.28) vs 39.05 (27.96) after confinement (p=0.028). The 
most frequent neuropsychiatric symptoms affected were apathy (4.15 (3.78) vs 5.75 (4.02); 
p=0.002) and anxiety (3.95 (3.73) vs 5.30 (4.01); p=0.006) in MCI patients and apathy (2.35 
(2.70) vs 3.75 (3.78); p=0.036), agitation (0.45 (1.14) vs 1.50 (2.66); p=0.029) and aberrant motor 
behaviour (1.25 (2.86) vs 2.00 (2.93); p=0.044) in AD patients. We did not observe differences in 
EuroQol-5D scores during the reevaluation. Approximately 30% of patients and 40% of caregivers 
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Conclusions
We have demonstrated the worsening of neuropsychiatric symptoms in patients with AD and MCI 
during 5 weeks of lockdown, with agitation, apathy and aberrant motor activity being the most 
affected symptoms.













Coronavirus disease 2019 (COVID-19) was described in Wuhan in December 2019 [1]. Since 
then, the number of cases and deaths have grown around the world, and the World Health 
Organization (WHO) declared the COVID-19 pandemic on March 11, 2020 [2]. In Spain, the first 
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patient with coronavirus was diagnosed on January 31. Today, the country borders on 219.764 
cases and 22.524 deaths [3]. There is not a worldwide or standard response to the pandemic, and 
each country is facing the crisis based on their own possibilities, expertise and hypotheses [4]. 
Although the pandemic affects the entire population globally, elderly subjects have the highest 
vital risk, and most of the deaths have occurred in those over 70 years of age [5]. In this age group, 
Alzheimer’s disease (AD) is highly prevalent. On March 14, the Spanish government decreed a 
state of alarm, prohibiting different types of people from going out into the streets, including all 
older people, along with the closure of day centres and centres where cognitive stimulation is 
carried out. Therefore, AD patients had to remain at home 24 hours a day, with a caregiver 
throughout the day as well. Given that these patients often have memory problems, they may have 
some difficulties understanding the situation, thus generating anxiety and nervousness for both 
them and their caregivers.
There are no data assessing the effect on neuropsychiatric symptoms and on the quality of life of 
this home confinement in patients with cognitive disorders and their caregivers.
Methods
We tested 40 subjects with a diagnosis of amnesic mild cognitive impairment (MCI) or mild AD 
recruited from the Cognitive Stimulation Program of Cognitive Disorders Unit at the Hospital 
Universitari Santa Maria (Lleida, Spain). The eligibility criteria included patients and their 
caregivers older than 60 years who were diagnosed with MCI [6] or mild AD (GDS 3-4) 
according to the NIA-AA criteria [7]. All patients underwent a previous evaluation as a normal 
procedure included in the Cognitive Stimulation Program of our unit. The patient, the responsible 
caregiver and the legal representative (when different from the responsible caregiver) signed an 
informed consent form during the first evaluation and provided oral acceptance previous to the 
second evaluation. 
Patients included in the Cognitive Stimulation Programme are all patients diagnosed of MCI or 
mild AD by those neurologist or geriatrician working in the unit. There are some exclusion criteria 
as: negative by the patient or caregiver to came to the hospital, sensorial difficulties that could 
make difficult to follow the stimulation sessions or uncontrolled behavior problems that could 
interfere with the development of the sessions. Those patients with mobility problems can go but 
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Our unit memory cares for patients with a wide geographical dispersion, so, the majority of 
patients who come to the stimulation workshops live in a diameter less than 20 km from the 
memory unit. 
The patients who started in the previous month were 42 subjects. All of them had a baseline 
assessment and two patients could not be contacted by telephone. All patients who were contacted 
(40) accepted to participate in the follow-up study. 
Those patients with a previous evaluation during the previous month to lockdown were called to 
participate in the study, and NPI and EuroQol-5D scores were obtained after 5 weeks of home 
confinement from phone interview, and the results were compared with those of the first 
evaluation.
Eligible patients and caregivers were subjected to the EuroQol-5D and Neuropsychiatric Inventory 
(NPI). The EuroQol-5D includes questions that evaluate different domains, such as mobility, 
personal self-care, instrumental activities of daily living, pain and depression. The caregiver 
answered in regard to themselves and the patient [8]. The NPI concerns the severity and frequency 
of the following 12 domains of behavioural functioning: delusions, hallucinations, 
agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability, 
aberrant motor activity, night-time behavioural disturbances, and appetite and eating abnormalities 
[9].
Availability of data
The data that support the findings of this study are available from the corresponding author upon 
reasonable request.
Statistical analyses
Descriptive statistics of the mean (standard deviation) or median [interquartile range] were 
estimated for quantitative variables with a normal or non-normal distribution, respectively. 
Absolute and relative frequencies were used for qualitative variables. The normality of the 
distribution was analysed using the Shapiro-Wilk test. The comparison of means was made by 
paired-samples Student’s t tests. The comparison between categorical variables was performed 
using the chi-squared test, Pearson’s test and Fisher’s exact test. The statistical study was 
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Results
We evaluated 40 patients: 20 with MCI and 20 with AD. The baseline characteristics of the 
sample are shown in table 1. Most of them (24) were living as the couple (60%) or were living 
alone (9) with an occasional caregiver (22.5%). Six of them (15%) had changed addresses in 
relation to confinement. The participants showed a significant worsening in neuropsychiatric 
symptoms: the preconfinement NPI score was 33.75 (22..28) vs 39.05 (27.96) after 5 weeks of 
domiciliary confinement (p=0.028).
Table 2 shows that agitation, apathy, and aberrant motor activity were the most affected 
neuropsychiatric symptoms in our patients. Other symptoms such as depression also worsened but 
without statistically significant differences. According to group, the neuropsychiatric symptoms 
worsened with a similar intensity in MCI (35.40 (21.15) vs 
39.95 (24.62); differences 4.5; p=0.103) and AD patients (32.10 (23.79) vs 38.15 (31.58); 
differences 6.0; p= 0.135). The most affected symptoms were apathy (4.15 (3.78) vs 5.75 (4.02); 
p=0.002) and anxiety (3.95 (3.73) vs 5.30 (4.01); p=0.006) for MCI patients. Apathy (2.35 (2.70) 
vs 3.75 (3.78); p=0.036) along with agitation (0.45 (1.14) vs 1.50 (2.66); p=0.029) and aberrant 
motor behaviour (1.25 (2.86) vs 2.00 (2.93); p=0.044) were the most common symptoms affected 
in AD patients.
The quality of life across the 5 weeks of lockdown did not show differences in patients (0.66 
[0.60;0.72] vs 0.62 [0.56;0.69]; differences -0.03 [-0.08;0.01]; p=0.456) or caregivers (0.74 
[0.68;0.80] vs 0.72 [0.65;0.79]; differences -0.02 [-0.06;0.02]; p=0.387). However, in terms of the 
EuroQol-5D, if the health condition had worsened after 5 weeks of confinement, 30% (12) of the 
patients and 40% (16) of the caregivers reported worsened scores. However, no differences were 
observed in the visual analogue scale scores both for the caregivers (69.88 (19.23) vs 65.50 
(23.66); p=0.101) and for the caregivers in reference to the patients (55.63 (16, 49) vs 52.88 
(20.28); p=0.123).
Discussion
In the present study, we investigated the impact of five weeks of lockdown in MCI and AD 
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the levels of agitation, apathy and aberrant motor activity. We did not observe a decrease in 
quality of life in either patients or caregivers. 
The COVID-19 pandemic is an unprecedented disaster and a significant psychological stressor, in 
addition to its tremendous impact on every facet of individuals' lives and organizations in virtually 
all social and economic sectors worldwide [10]. In the general population, the increasing burden 
of the epidemic has led to a global atmosphere of anxiety and depression [11].
AD patients are a particularly vulnerable population. Most of them have memory problems that 
can make it difficult to understand what is happening. As in most of the 
population, their routines have been altered, and their environment may be more chaotic due to the 
uncertainties caused by the pandemic. Furthermore, their stimulation programmes have been 
interrupted or severely modified. All these circumstances can generate important alterations in 
these patients [12].
A longitudinal study of the general population showed that depression, anxiety and stress 
increased longitudinally during the pandemic in China. We observed that the neuropsychiatric 
symptoms and quality of life of patients and caregivers were affected in patients with cognitive 
impairment.
Patients included in Cognitive Stimulation Program go to the hospital 3 times for week to do 
physical and cognitive stimulation. The works according their cognitive statment, so patients 
included in the study were in two different groups. 
Our patients showed worsening agitation, apathy, and aberrant motor activity after 5 weeks of 
lockdown in the MCI and AD Spanish population. There are no previous studies that have 
evaluated these changes in patients with memory problems. We did not observe changes according 
to quality of life, but many patients and caregivers said that their health condition had worsened 
after confinement.
Several strategies to try to improve the AD patients situation during COVID pandemic have been 
published by different associations or entities [12-14]. According with our results, we insist on the 
need for the use and dissemination of this information throughout the community of AD patients.
Despite the limitations in the extension of the tests used, no previous information on this type of 
patient in these exceptional circumstances has been reported. However, some limitations needs to 
be considered. One limitation is that the first evaluation was from personal interview and the 
second was from phone interview. This could explain some differences but the interview was 
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is that our patients go to the unit memory 3 days for week. This could explain that the change of 
routine can affect these patients and worse neuropsychiatric symptoms. However, these patients 
started the program one month before the lockdown when they were evaluated. So, perhaps they 
had not yet acquired this routine.
In this study, we underline the need to take into account the particular characteristics of patients 
with cognitive impairment when developing measures of de-escalation during confinement to try 
to minimize the effects on neuropsychiatric symptoms and quality of life in patients.
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le Table 1. Descriptive characteristics of mild cognitive impairment and moderate Alzheimer’s disease patients.Global MCI AD pAge (SD) 77.4 (5.25) 77.3 (4.05) 77.5 (6.33) 0.049
Women (%) 24 (60.0%) 10 (50.5%) 14 (70.0%) 0.167
MMSE (SD) 23.1 (3.76) 25.3 (2.77) 20.9 (3.37) 0.433
Married (%) 25 (62.5%) 13 (65.0%) 8 (40.0%) 0.596
Non‐professional caregiver 39 (97,5%) 19 (95.0%) 20 (100%) 0.503
Hypertension (%) 24 (60.0%) 9 (45.0%) 15 (75.0%) 0.053
Diabetes (%) 12 (30.0%) 7 (35.0%) 5 (25.0%) 0.366
Dislipidemia(%) 21 (52,5%) 10 (50.5%) 11 (55.0%) 0.514
Psychiatric treatment (%) 22 (55,0%) 12 (60.0%) 10 (50.0%) 0.376
Acetilcholinesterasa inhibitors (%) 21 (52,5%) 5 (25.0%) 16 (80.0%) 0.001
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Table 2. Changes in neuropsychiatric symptoms included in the Neuropsychiatric Inventory 
from baseline to 5 weeks of lockdown due to the COVID-19 pandemic. 
Prelockdown 5 weeks lockdown p
Stress 9.85 (7.75) 10.33 (8.29) 0.554
Delusions 0.63 (1.90) 0.75 (2.20) 0.565
Hallucinations 0.20 (0.72) 0.15 (0.70) 0.700
Agitation/aggression 0.68 (1.50) 1.50 (2.58) 0.020
Depression/dysphoria 2.25 (3.06) 2.50 (3.49) 0.602
Anxiety 4.73 (3.92) 5.18 (4.34) 0.458
Euphoria 0.53 (1.24) 0.43 (1.48) 0.514
Apathy 3.25 (3.37) 4.75 (3.98) 0.000
Desinhibition 0.85 (1.62) 0.82 (1.55) 0.852
Irritability/lability 3.33 (3.14) 3.83 (3.80) 0.278
Aberrant motor behaviour 1.15 (2.58) 1.83 (2.84) 0.019
Night-time behavioral disturbances 2.45 (3.57) 2.80 (3.40) 0.548
Appetite/eating disorders 3.88 (4.88) 4.20 (4.93) 0.537
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